There is a clinical need to determine whether women with HER-2-positive/COX-2-positive DCIS represent a high-risk patient population for disease progression or local recurrence; this cohort especially may benefit form COX-2 inhibitor therapy. Here, ERBB2 is linked to ductal breast carcinoma in situ.